RxDoctor Payments Data

Larry Griffith, MD

Family Medicine · Glendale, AZNPI 1588607444

Payments from drug & device makers

$4,190in general payments, 2019–2025

Across 140 payments — averaging $29.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Lilly USA, LLC$737
  • Sanofi-aventis U.S. LLC$192
  • GSK$144
  • Boehringer Ingelheim$107
  • Exact Sciences$84
  • plus $375 from 9 others

What the payments were for

  • Food & beverage$4,184100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,190 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$56,209
Medicare patients
111
Services billed
725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol73$87,410
JardianceEmpagliflozin55$84,909
MounjaroTirzepatide30$50,028
TrulicityDulaglutide18$31,992
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$30,522
EliquisApixaban30$29,266
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$18,308
Lyumjev Kwikpen U-100Insulin Lispro-Aabc11$13,785
SynthroidLevothyroxine Sodium68$7,892
Rosuvastatin Calcium371$4,938
Celecoxib65$4,323
Ezetimibe111$3,632
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,534
Pioglitazone Hcl154$2,262
Tramadol Hcl79$1,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,550$87,41073 claims
Boehringer IngelheimJardiance$107$84,90955 claims
Lilly USA, LLCMounjaro, Trulicity$737$82,02048 claims
GSKTrelegy Ellipta$144$30,52240 claims
PfizerEliquis$78$29,26630 claims
AbbVieSynthroid$75$7,89268 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →